PHIO - Phio CEO to Speak at Wainwright Conference in New York in September | Benzinga
MARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its President and CEO, Robert Bitterman, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11th.
Mr. Bitterman will discuss the recent FDA IND approvals for Phio's lead product, PH-762; PH-762 is currently cleared for two clinical trials. Mr. Bitterman will also review the Company's evolution from discovery to development, highlighting the new, industry-experienced leadership team he has put in place to lead this transformation.
The presentation will become available online at 7:00 am EST on Monday, September 11th. It will be streamed here.
The Conference will be taking place September 11th—13th at the Lotte New York Palace Hotel in New York City.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells ...